FDA panel votes to place popular peptide BPC-157 on compounding list

An FDA advisory panel voted 8-6 to place BPC-157, a widely used peptide, on the compounding list, which would allow pharmacies to compound it more broadly without FDA approval for each formulation.

This Wire brief sits within Fusion42's coverage of Digital Health. Wire is Fusion42's founder-focused intelligence feed: each story is connected to the funds and startups it names — every one with a live profile on Raise or Scout — so founders can follow the capital and the momentum behind the headline rather than just the headline itself. Wire analysis is one of the live surfaces Arthur reasons over.